Cara Therapeutics | CARA - Cost Of Sales


Cara Therapeutics reported $0 in Cost of Sales for its fiscal quarter ending in March of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Assertio Holdings USD 8.89M 2.29M Jun/2024
Cara Therapeutics USD 0 0 Mar/2025
Cassava Sciences USD 3.96M 1.16M Sep/2025
Chugai Pharma JPY 87.56B 12.68B Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 3.54M 1.89M Dec/2025
CSL USD 3.87B 2.08B Dec/2025
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
J&J USD 7.97B 689M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
RedHill Biopharma USD 702K 0 Jun/2024
Supernus Pharmaceuticals USD 47.53M 4.24M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024